The metabolic syndrome and risk of myocardial infarction in familial hypertension (Hypertension Heredity in Malmö Evaluation study)

Journal of Hypertension

Volumn 27, Issue 1, 2009, Pages 109-117

  Fedorowski, Artur ^a   Burri, Philippe ^a   Hulthén, Lennart ^b   Melander, Olle ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cardiovascular diseases; Dyslipidemia; Genetic hypertension; Insulin resistance; Metabolic syndrome; Microalbuminuria; Myocardial infarction

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; EDUCATION PROGRAM; ESSENTIAL HYPERTENSION; FAMILIA; FEMALE; GENETIC COMPATIBILITY; HEART INFARCTION; HEREDITARY HYPERTENSION; HUMAN; INCIDENCE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELATIVE; RISK; SMOKING; WORLD HEALTH ORGANIZATION; BLOOD; GENETICS; HYPERTENSION; MIDDLE AGED;

ADULT; AGED; CHOLESTEROL, HDL; FEMALE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK;

EID: 58849160083     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328314b80a     Document Type: Article

References (38)

1. vonWowern F, Bengtsson K, Lindgren CM, Orho-Melander M, Fyhrquist F, Lindblad U, et al. A genome wide scan for early onset primary hypertension in Scandinavians. Hum Mol Genet 2003; 12:2077-2081.
2. Hunt SC, Williams RR, Barlow GK. A comparison of positive family history de?nitions for de?ning risk of future disease [published erratum appears in J Chronic Dis 1987; 40:369]. J Chronic Dis 1986; 39:809-821.
3. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, raziadei L, et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317:350-357.
4. Endre T, Mattiasson I, Berglund G, Hulthen UL. Insulin and renal sodium retention in hypertension-prone men. Hypertension 1994; 23:313-319.
5. Vlasakova Z, Pelikanova T, Karasova L, Skibova J. Insulin secretion, sensitivity, and metabolic pro?le of young healthy offspring of hypertensive parents. Metabolism 2004; 53:469-475.
6. Kannel WB. Framingham study insights into hypertensive risk of cardiovascular disease. Hypertens Res 1995; 18:181-196.
7. Hedblad B, Nilsson P, Engstrom G, Berglund G, Janzon L. Insulin resistance in nondiabetic subjects is associated with increased incidence of myocardial infarction and death. Diabet Med 2002; 19:470-475.
8. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607.
9. Hauner H. Insulin resistance and themetabolic syndrome-a challenge of the new millennium. Eur J Clin Nutr 2002; 56 (Suppl 1):S25-S29.
10. Alberti KG, Zimmet PZ. De?nition, diagnosis and classi?cation of diabetes mellitus and its complications. Part 1: diagnosis and classi?cation of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15:539-553.
11. III ATP. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) ?nal report. Circulation 2002; 106:3143-3421.
12. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome: a new world-wide de?nition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23:469-480.
13. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scienti?c Statement. Circulation 2005; 112:2735-2752.
14. Qiao Q. Comparison of different de?nitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women. Diabetologia 2006; 49:2837-2846.
15. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24:683-689.
16. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004; 164:1066-1076.
17. McNeill AM, RosamondWD, Girman CJ,Golden SH, Schmidt MI, East HE, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005; 28:385-390.
18. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28:1769-1778.
19. Mancia G, Bombelli M, Corrao G, Facchetti R, Madotto F, Giannattasio C, et al. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension 2007; 49:40-47.
20. Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization de?nitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 2007; 30:8-13.
21. Nilsson PM, Engstrom G, Hedblad B. The metabolic syndrome and incidence of cardiovascular disease in nondiabetic subjects: a population-based study comparing three different de?nitions. Diabet Med 2007; 24:464-472.
22. Girman CJ, Rhodes T, Mercuri M, Pyorala K, Kjekshus J, Pedersen TR, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004; 93:136-141.
23. Schillaci G, Pirro M, Vaudo G, Gemelli F, Marchesi S, Porcellati C, et al. Prognostic value of the metabolic syndrome in essential hypertension. Jam Coll Cardiol 2004; 43:1817-1822.
24. Berglund G, Nilsson P, Eriksson KF, Nilsson JA, Hedblad B, Kristenson H, et al. Long-term outcome of the Malmo preventive project: mortality and cardiovascular morbidity. J Intern Med 2000; 247:19-29.
25. Wirfalt E, Mattisson I, Johansson U, Gullberg B, Wallstrom P, Berglund G. A methodological report from the Malmo Diet and Cancer study: development and evaluation of altered routines in dietary data processing. Nutr J 2002; 1:1-16.
26. O'Brien E, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G, et al. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens 2003; 21:821-848.
27. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Atherosclerosis 2004; 173:381-391.
28. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999; 48:937-942.
29. Wannamethee SG, Shaper AG, Lennon L,Morris RW.Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 2005; 165:2644-2650.
30. Conroy RM, Pyorala K, Fitzgerald AP, Sans S,Menotti A, De BackerG, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24:987-1003.
31. Wolfram RM, Brewer HB, Xue Z, Satler LF, Pichard AD, Kent KM, et al. Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with non-ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation. Am J Cardiol 2006; 98:711-717.
32. Shlipak MG, Ix JH, Bibbins-Domingo K, Lin F, Whooley MA. Biomarkers to predict recurrent cardiovascular disease: the Heart and Soul Study. Am J Med 2008; 121:50-57.
33. Jeppesen J, Hansen TW, Rasmussen S, Ibsen H, Torp-Pedersen C, Madsbad S. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study. J AmCollCardiol 2007; 49:2112-2119.
34. Wilhelmsen L, Rosengren A, Johansson S, Lappas G. Coronary heart disease attack rate, incidence and mortality 1975-1994 in Goteborg, Sweden. Eur Heart J 1997; 18:572-581.
35. Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004; 109:42-46.
36. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81 (4A):7B-12B.
37. Milionis HJ, Kostapanos MS, Liberopoulos EN, Goudevenos J, Athyros VG, Mikhailidis DP, et al. Different de?nitions of the metabolic syndrome and risk of ?rst-ever acute ischaemic nonembolic stroke in elderly subjects. Int J Clin Pract 2007; 61:545-551.
38. Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 2007; 92:399-404.